Skip to main content
SpringerLink
Log in

CANCER

EGFR ligands dictate tumour suppression

  • News & Views
  • Published:

From Nature Cell Biology

View current issue Submit your manuscript

EGFR is an oncogene that is frequently amplified in glioblastoma. A new study suggests a tumour-suppressive role of EGFR in EGFR-amplified glioblastoma regulated by ligand abundance. Increased EGFR ligand in EGFR-amplified glioblastoma suppresses invasion by upregulating BIN3 and inhibiting activation of Rho GTPases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: EGFR directs two distinct and mutually exclusive signalling pathways: constitutive signalling and ligand-activated signalling.

References

  1. Louis, D. N. et al. Neuro Oncol. 23, 1231–1251 (2021).

    Article  CAS  Google Scholar 

  2. Dirks, P. B. et al. Clin. Cancer Res. 26, 2457–2460 (2020).

    Article  Google Scholar 

  3. Brennan, C. W. et al. Cell 155, 462–477 (2013).

    Article  CAS  Google Scholar 

  4. Fan, Q. W. et al. Cancer Cell 24, 438–449 (2013).

    Article  CAS  Google Scholar 

  5. Chakraborty, S. et al. Nat. Commun. 5, 5811 (2014).

    Article  CAS  Google Scholar 

  6. Singh, B. et al. F1000 Res. https://doi.org/10.12688/f1000research.9025.1 (2016).

    Article  Google Scholar 

  7. Hu, C. et al. Nature 602, 518–522 (2022).

    Article  CAS  Google Scholar 

  8. Guo, G. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-022-00962-4 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  9. An, Z. et al. Oncogene 37, 1561–1575 (2018).

    Article  CAS  Google Scholar 

  10. de Vries, N. A. et al. Invest. New Drugs 30, 443–449 (2012).

    Article  CAS  Google Scholar 

  11. Barkovich, K. J. et al. Cancer Discov. 2, 450–457 (2012).

    Article  CAS  Google Scholar 

  12. Ramnarain, D. B. et al. Cancer Res. 66, 867–874 (2006).

    Article  CAS  Google Scholar 

  13. Prendergast, G. C. et al. Biochim. Biophys. Acta 1796, 25–36 (2009).

    Google Scholar 

  14. Murray, D. W. et al. Br. J. Cancer 110, 1307–1315 (2014).

    Article  CAS  Google Scholar 

  15. Ramnarain, D. B. et al. Cancer Res. 66, 867–874 (2006).

    Article  CAS  Google Scholar 

  16. Le Rhun, E. et al. Cancer Treat. Rev. 80, 101896 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Scientist Training Program and Graduate Program in Biomedical Sciences, University of California, San Francisco, CA, USA

    Mary Clare Beytagh & William A. Weiss

  2. Department of Neurology, University of California, San Francisco, CA, USA

    William A. Weiss

  3. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA

    William A. Weiss

  4. Departments of Pediatrics and Neurological Surgery, University of California, San Francisco, CA, USA

    William A. Weiss

Authors
  1. Mary Clare Beytagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William A. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William A. Weiss.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beytagh, M.C., Weiss, W.A. EGFR ligands dictate tumour suppression. Nat Cell Biol 24, 1189–1191 (2022). https://doi.org/10.1038/s41556-022-00967-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41556-022-00967-z

  • Springer Nature Limited

Search

Navigation